Protalix BioTherapeutics (NYSE:PLX) Upgraded at StockNews.com

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a buy rating to a strong-buy rating in a report released on Wednesday.

Separately, HC Wainwright increased their target price on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 3rd.

Protalix BioTherapeutics Stock Performance

PLX stock opened at $2.24 on Wednesday. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.76. The business’s 50-day moving average is $2.38 and its two-hundred day moving average is $1.70. The company has a market cap of $164.94 million, a price-to-earnings ratio of -17.23 and a beta of 0.72.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PLX. Northern Trust Corp raised its stake in shares of Protalix BioTherapeutics by 1,299.4% in the fourth quarter. Northern Trust Corp now owns 731,742 shares of the company’s stock worth $1,376,000 after buying an additional 679,451 shares during the period. Renaissance Technologies LLC raised its stake in shares of Protalix BioTherapeutics by 17.0% in the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company’s stock worth $2,102,000 after buying an additional 162,100 shares during the period. Marshall Wace LLP bought a new position in shares of Protalix BioTherapeutics in the fourth quarter worth about $192,000. Jane Street Group LLC raised its stake in shares of Protalix BioTherapeutics by 147.2% in the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company’s stock worth $214,000 after buying an additional 67,664 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Protalix BioTherapeutics in the third quarter worth about $44,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.